hCG (Human Chorionic Gonadotropin)

What is Human Chorionic Gonadotropin (hCG)?

Human Chorionic Gonadotropin, or hCG, is a hormone medication given by injection to help with fertility treatments and certain hormone problems. This is the same hormone that a woman's body makes naturally during pregnancy. When used as a medicine, hCG helps trigger ovulation (egg release) in women undergoing fertility treatments, or helps men's bodies make testosterone when they have hormone deficiencies. Your doctor prescribes this medication as part of a carefully monitored treatment plan to help you achieve your reproductive or hormone health goals.

How Does hCG Work and What Is It Used For?

In women receiving fertility treatments, hCG works like the natural hormone surge that causes your ovary to release a mature egg. Your doctor will monitor your ovaries with ultrasound and blood tests, and when your eggs are ready, you'll receive an hCG injection. The egg is then released about 36-40 hours later, allowing for the best timing of insemination or egg retrieval procedures. This medication is commonly used in IVF (in vitro fertilization), IUI (intrauterine insemination), and other fertility treatments. In men with certain hormone deficiencies, hCG injections help the testicles produce testosterone naturally, which is especially important if you want to maintain your fertility while treating low testosterone. The medication may also be used in young boys to help undescended testicles move into the proper position.

How to Take This Medication

HCG is given as an injection either under the skin (subcutaneous) or into the muscle (intramuscular). Your healthcare provider will teach you or your partner how to give these injections at home, or you may receive them at your doctor's office. The medication comes as a powder that must be mixed with liquid right before injection. It's very important to take hCG exactly when your doctor tells you to—timing is critical for fertility treatments, often scheduled for a specific time of day. Store unmixed medication in the refrigerator and protect it from light. Once mixed, use it right away and throw away any leftover medication. Rotate your injection sites (different areas of your abdomen, thigh, or buttocks) to prevent soreness. The dose varies widely depending on why you're taking it: fertility treatments typically use 5,000-10,000 units as a single dose, while men taking it for testosterone production usually receive 1,500-3,000 units two to three times per week.

Common Side Effects and When to Call Your Doctor

Most people tolerate hCG well, but you may experience some side effects. Common, mild side effects include pain, redness, or bruising where you inject the medication, headaches, tiredness, mood changes, breast tenderness, and mild bloating or abdominal discomfort. These usually don't require medical attention unless they become severe. However, you should call your doctor right away if you experience severe abdominal pain or swelling, rapid weight gain (more than 2-3 pounds in a day), severe nausea or vomiting that won't stop, decreased urination, severe shortness of breath, or chest pain. These could be signs of a serious condition called ovarian hyperstimulation syndrome (OHSS) or blood clots, which require immediate medical attention. Women should also contact their doctor if they have severe pelvic pain on one side, which could indicate ovarian torsion (twisted ovary). Men may notice breast enlargement or tenderness, which should be reported to your doctor.

Important Warnings and Precautions

Do not use hCG if you are already pregnant, have a history of hormone-related cancers (breast, ovarian, uterine, or prostate cancer), have blood clots or a history of blood clots, or are allergic to hCG or similar medications. Tell your doctor about all your medical conditions, especially thyroid problems, heart disease, kidney disease, asthma, epilepsy, or migraines, as hCG can cause fluid retention that may worsen these conditions. Women undergoing fertility treatment should understand that hCG increases your chances of having twins or triplets, and there is a small risk of serious complications including OHSS and blood clots. Your doctor will monitor you closely with ultrasounds and blood tests to minimize these risks. Some fertility cycles may need to be cancelled if too many eggs are developing, to keep you safe. If you become pregnant after hCG treatment, there is a slightly higher risk of ectopic pregnancy (pregnancy outside the uterus), so early pregnancy monitoring is important. This medication should only be used under close medical supervision as part of a comprehensive fertility or hormone treatment program. Never use hCG for weight loss—this is not an approved use and can be dangerous. Keep all your monitoring appointments, as your doctor needs to check your response to treatment and watch for complications.

Human Chorionic Gonadotropin (hCG) is a naturally occurring glycoprotein hormone that was first isolated from the urine of pregnant women in the 1920s and has since become an essential therapeutic agent in reproductive endocrinology. The hormone is produced by placental syncytiotrophoblast cells during pregnancy and serves as the biological basis for most pregnancy tests. Pharmaceutical hCG preparations were initially derived from the urine of pregnant women (urinary hCG) and later through recombinant DNA technology (recombinant hCG or r-hCG), providing standardized, purified formulations for clinical use. The FDA has approved various hCG formulations for multiple indications spanning reproductive medicine, pediatric endocrinology, and male hypogonadism treatment.

In reproductive medicine, hCG has become indispensable in assisted reproductive technology (ART) protocols, where it serves as the primary agent for triggering final oocyte maturation in controlled ovarian stimulation cycles. When administered at the appropriate follicular development stage, typically when lead follicles reach 17-20mm diameter, hCG mimics the natural LH surge that precipitates ovulation, allowing precise timing of oocyte retrieval for in vitro fertilization (IVF) or intrauterine insemination (IUI) procedures. The medication is also used in ovulation induction protocols for anovulatory infertility, frozen embryo transfer cycles to support luteal phase function, and as part of dual-trigger protocols combining hCG with GnRH agonists to optimize oocyte maturation while minimizing ovarian hyperstimulation syndrome (OHSS) risk in high-responder patients.

Beyond female reproductive applications, hCG plays a critical role in treating male hypogonadotropic hypogonadism, a condition characterized by insufficient gonadotropin secretion leading to testosterone deficiency and impaired spermatogenesis. In these patients, hCG administration stimulates endogenous testosterone production by Leydig cells, offering an alternative to exogenous testosterone replacement that preserves fertility potential. The medication is particularly valuable when fertility is desired, as it can initiate or maintain spermatogenesis when combined with FSH or human menopausal gonadotropin (hMG). In pediatric populations, hCG is approved for treating prepubertal cryptorchidism (undescended testes) by stimulating testicular descent through hormonal stimulation, though surgical intervention remains the definitive treatment for most cases.

Emerging applications of hCG extend beyond traditional reproductive indications. Research has explored its immunomodulatory properties in treating life-threatening acute graft-versus-host disease (aGVHD) following hematopoietic stem cell transplantation, with clinical trials investigating doses of 2,000-5,000 units/m² administered every other day in combination with standard immunosuppression. Additional investigational uses include prevention of preterm labor through its effects on uterine contractility and myometrial relaxation. The versatility of hCG across multiple physiological systems reflects its fundamental role in reproductive biology and endocrine regulation.

Current clinical practice emphasizes individualized hCG dosing based on patient characteristics, treatment indication, and response to ovarian stimulation. Standard doses range from 5,000-10,000 international units for ovulation triggering, with lower doses (1,500-3,000 units) employed in dual-trigger protocols or high-responder patients at elevated OHSS risk. The shift toward personalized medicine in reproductive endocrinology has refined hCG utilization, incorporating patient-specific factors such as anti-Müllerian hormone (AMH) levels, antral follicle count, body mass index, and prior treatment response to optimize outcomes while minimizing complications. As ART success rates continue to improve and our understanding of reproductive physiology deepens, hCG remains a cornerstone therapeutic agent with evolving applications in reproductive and endocrine medicine.

Human Chorionic Gonadotropin is a heterodimeric glycoprotein hormone composed of an alpha subunit (shared with luteinizing hormone, follicle-stimulating hormone, and thyroid-stimulating hormone) and a unique beta subunit that confers biological specificity. hCG exerts its physiological effects by binding to and activating the luteinizing hormone/chorionic gonadotropin receptor (LHCGR), a G-protein coupled receptor expressed primarily on gonadal cells including ovarian granulosa cells, luteal cells, testicular Leydig cells, and theca cells.

Upon receptor binding, hCG activates multiple intracellular signaling cascades, predominantly through the Gs protein-adenylyl cyclase-cyclic AMP (cAMP) pathway. This leads to activation of protein kinase A (PKA) and subsequent phosphorylation of downstream targets including steroidogenic acute regulatory protein (StAR) and various steroidogenic enzymes. In ovarian tissue, hCG stimulation of granulosa and theca cells promotes the final maturation of ovarian follicles, triggers ovulation through proteolytic enzyme activation and follicular wall rupture, and supports corpus luteum formation and progesterone production essential for early pregnancy maintenance.

In testicular Leydig cells, hCG binding stimulates testosterone biosynthesis through upregulation of cholesterol transport into mitochondria and activation of the steroidogenic enzyme cascade, including cholesterol side-chain cleavage enzyme (CYP11A1), 3β-hydroxysteroid dehydrogenase, 17α-hydroxylase/17,20-lyase (CYP17A1), and 17β-hydroxysteroid dehydrogenase. This androgenic effect is exploited therapeutically in treating hypogonadotropic hypogonadism and cryptorchidism. The hormone also exhibits immunomodulatory properties through effects on regulatory T cells and cytokine production, which has led to investigation of its use in conditions such as acute graft-versus-host disease.

The duration of hCG action is prolonged compared to endogenous LH due to its longer half-life (approximately 24-36 hours), attributed to extensive glycosylation that protects against rapid degradation and renal clearance. This extended biological activity allows for sustained receptor occupancy and prolonged stimulation of target tissues, making single-dose administration effective for triggering ovulation and supporting early luteal phase function in assisted reproductive technology protocols.

Ovulation Induction and Assisted Reproductive Technology

Standard Ovulation Triggering

For final oocyte maturation in controlled ovarian stimulation cycles, administer 5,000-10,000 IU as a single intramuscular or subcutaneous injection when ultrasound monitoring demonstrates adequate follicular development (typically ≥2-3 follicles measuring 17-20mm diameter) and serum estradiol levels are appropriate for the number of mature follicles. Ovulation occurs approximately 36-42 hours post-administration. For IVF/ICSI procedures, schedule oocyte retrieval 34-36 hours after hCG injection. For intrauterine insemination, perform the procedure 36-40 hours post-hCG administration.

Dosing by patient profile:

• Normal responders: 5,000-10,000 IU single dose

• Poor responders/diminished ovarian reserve: 10,000 IU single dose

• High responders/PCOS patients: 5,000 IU single dose or consider dual-trigger protocol

• Mild male factor infertility with ovulation induction: 10,000 IU single dose

Dual-Trigger Protocols (High Responders)

For patients at elevated OHSS risk (>15-20 follicles ≥11mm, estradiol >3,000-4,000 pg/mL, PCOS, prior OHSS):

• Low-dose hCG 1,000-2,000 IU PLUS GnRH agonist (leuprolide 4mg or triptorelin 0.2mg) administered simultaneously 35-36 hours before oocyte retrieval

• Alternative: hCG 1,500 IU single dose with GnRH agonist trigger

• Booster dose: 1,500 IU on day of oocyte retrieval may be administered in some protocols

Luteal Phase Support

For frozen embryo transfer cycles:

• 1,500 IU single subcutaneous injection at onset of progesterone supplementation

• Improves implantation and live birth rates by 6-10%

• Administer on day of progesterone initiation in hormone replacement protocols

Male Hypogonadotropic Hypogonadism

Testosterone Replacement

Initial therapy:

• 1,500-3,000 IU intramuscularly 2-3 times per week

• Continue for 3-6 months to achieve physiological testosterone levels (400-700 ng/dL)

• Monitor serum testosterone 48-72 hours after injection during dose titration

• Adjust dose based on testosterone response and clinical symptoms

Spermatogenesis Induction

When pregnancy is desired in hypogonadal males:

• hCG 3,000 IU three times weekly (Monday/Wednesday/Friday) intramuscularly

• Continue hCG monotherapy for 6 months to optimize Leydig cell function and intratesticular testosterone

• If spermatogenesis not achieved, add recombinant FSH 75-150 IU three times weekly or hMG 75-150 IU three times weekly

• Continue combination therapy for 12-24 months, monitoring semen analysis every 3 months

• Expected outcomes: 60-80% achieve spermatogenesis, 40-60% achieve sperm counts adequate for conception

Adolescent Males with Congenital Hypogonadotropic Hypogonadism

Pubertal induction protocol:

• Initial priming period: May use corifollitropin alfa alone for 12 weeks (investigational)

• hCG 500-5,000 IU twice weekly subcutaneously

• Start with lower doses (500-1,000 IU) and titrate upward every 8-12 weeks

• Adjust dose to maintain total testosterone 400-700 ng/dL and estradiol within protocol-specified ranges

• Continue for 52-64 weeks to achieve adult testicular volumes and induce spermatogenesis

• Monitor testosterone, estradiol, testicular volume, and pubertal development every 3 months

Prepubertal Cryptorchidism

Standard regimen:

• 1,000-2,000 IU intramuscularly 2-3 times per week for 4-6 weeks

• Alternative: 4,000 IU three times weekly for 3 weeks

• Success rates: 20-30% for testicular descent

• Typically attempted before age 2 years; surgical orchiopexy remains definitive treatment

Investigational Indications

Acute Graft-Versus-Host Disease

First-line therapy (high-risk patients):

• 2,000 units/m² every other day for 1 week with methylprednisolone 48 mg/m²/day

• Maintenance (if CR/PR achieved): 2,000 units/m² twice weekly for 5 weeks (weeks 6-10)

Second-line therapy (steroid-refractory):

• 2,000-5,000 units/m² every other day for 2 weeks plus standard immunosuppression

• Dose selection based on organ severity

• Maintenance (if CR/PR achieved): 2,000-5,000 units/m² twice weekly for 5 weeks (weeks 3-7)

Preterm Labor Prevention

• 1,500-3,000 IU single dose (investigational)

• Administered in threatened preterm labor scenarios

• Limited clinical data; not standard of care

Administration and Preparation

Reconstitution (lyophilized powder):

1. Inject supplied diluent into vial containing hCG powder

2. Swirl gently; do not shake vigorously

3. Inspect for particulate matter and discoloration

4. Use immediately after reconstitution; discard unused portions

Injection technique:

• Intramuscular: Inject into gluteal muscle or vastus lateralis using 22-25 gauge needle

• Subcutaneous: Inject into abdomen, thigh, or upper arm using 25-27 gauge needle

• Rotate injection sites to minimize local reactions

Storage:

• Unreconstituted: Refrigerate at 2-8°C (36-46°F); protect from light

• Reconstituted: Use immediately; do not store

• Pre-filled syringes: Refrigerate; check product-specific storage requirements

Special Populations

Renal impairment: No dose adjustment typically required; monitor for prolonged effects

Hepatic impairment: No dose adjustment required

Geriatric patients: Not typically used in elderly populations

Pediatric patients: Use only for approved indication (cryptorchidism) or specialized protocols (adolescent hypogonadism) under endocrinology supervision

Monitoring Parameters

• Fertility treatments: Ultrasound follicular monitoring, serum estradiol, progesterone (luteal phase), pregnancy test

• Male hypogonadism: Serum testosterone (48-72 hours post-injection), LH, FSH, estradiol, semen analysis (if fertility desired), testicular volume

• OHSS surveillance: Daily weights, abdominal girth, symptoms (abdominal pain, nausea, vomiting), hematocrit, electrolytes, renal function if symptomatic

• All patients: Injection site reactions, signs of hypersensitivity

The clinical efficacy of human chorionic gonadotropin has been extensively validated across multiple indications through randomized controlled trials, cohort studies, and meta-analyses spanning several decades of reproductive medicine practice. In assisted reproductive technology, hCG serves as the gold standard for triggering final oocyte maturation, with success rates well-established across diverse patient populations. Large-scale studies in IVF/ICSI cycles demonstrate that hCG administration (typically 5,000-10,000 IU) when lead follicles reach 17-20mm diameter results in oocyte retrieval rates of 85-95%, with 70-80% of retrieved oocytes demonstrating appropriate nuclear maturity (metaphase II stage). Clinical pregnancy rates following hCG-triggered cycles range from 30-50% per embryo transfer depending on patient age, ovarian reserve, and embryo quality, with live birth rates of 25-40% per initiated cycle in good-prognosis patients.

Comparative effectiveness research has evaluated optimal hCG dosing strategies and alternative triggering protocols. Studies comparing standard-dose hCG (10,000 IU) versus low-dose hCG (5,000 IU) in normal responders show equivalent oocyte maturation rates and pregnancy outcomes, while low-dose protocols demonstrate reduced OHSS incidence. In high-responder patients with polycystic ovary syndrome or elevated estradiol levels (>3,000-4,000 pg/mL), dual-trigger protocols combining reduced-dose hCG (1,000-2,000 IU) with GnRH agonist (0.2mg triptorelin or 4mg leuprolide) have shown superior outcomes compared to GnRH agonist alone, with meta-analyses demonstrating 20-30% higher live birth rates while maintaining low OHSS risk. Clinical trials in frozen embryo transfer cycles have investigated luteal phase hCG supplementation, with studies showing that single-dose hCG (1,500 IU) administration at progesterone initiation improves clinical pregnancy rates by 8-12% and live birth rates by 6-10% compared to progesterone alone.

In male hypogonadotropic hypogonadism, clinical evidence supports hCG as effective monotherapy for testosterone restoration and combination therapy with FSH for spermatogenesis induction. Prospective studies demonstrate that hCG doses of 1,500-3,000 IU administered 2-3 times weekly achieve physiological testosterone levels (400-700 ng/dL) in 80-90% of patients within 3-6 months. When fertility is desired, combination therapy with hCG plus recombinant FSH (75-150 IU three times weekly) or hMG induces spermatogenesis in 60-80% of previously azoospermic men, with sperm concentrations sufficient for natural conception or assisted reproduction achieved in 40-60% after 12-24 months of treatment. A landmark study of adolescent males with congenital hypogonadotropic hypogonadism demonstrated that hCG doses of 500-5,000 IU twice weekly (adjusted to maintain testosterone 400-700 ng/dL) successfully induced pubertal development, with 90% achieving adult testicular volumes and 70% demonstrating spermatogenesis after 52-64 weeks of therapy.

Emerging clinical evidence explores novel hCG applications beyond traditional reproductive indications. Phase II clinical trials investigating hCG in life-threatening acute graft-versus-host disease have shown promising results, with one study reporting that hCG (2,000-5,000 units/m² every other day for 2 weeks, then twice weekly for 5 weeks) combined with standard immunosuppression achieved complete or partial response in 65% of patients with steroid-refractory aGVHD, compared to 35% with standard therapy alone. Smaller studies have examined hCG for preterm labor prevention, with single doses of 1,500-3,000 IU demonstrating potential to prolong pregnancy by 2-4 weeks in women with threatened preterm delivery, though larger confirmatory trials are needed. In veterinary reproductive medicine, controlled studies demonstrate hCG effectiveness for ovulation induction across multiple species, with dose-response relationships established for cattle (1,000-3,300 IU), zebrafish, and amphibians, providing comparative biological insights into LH/CG receptor pharmacology.

Safety data from clinical trials consistently identify ovarian hyperstimulation syndrome as the primary serious adverse event associated with hCG use in fertility treatments, with incidence rates of 1-3% for moderate-to-severe OHSS in standard protocols and <1% when risk-reduction strategies are employed. Long-term follow-up studies of children conceived through hCG-triggered ART cycles show no increased risks of congenital anomalies, developmental delays, or childhood cancers compared to naturally conceived children, providing reassurance regarding reproductive safety. Meta-analyses examining thromboembolic risk associated with hCG administration in ART show small absolute risk increases (0.1-0.3%) primarily in patients with additional risk factors, supporting the importance of individualized risk assessment and appropriate thromboprophylaxis in high-risk populations.

Absolute Contraindications

Human Chorionic Gonadotropin is absolutely contraindicated in the following conditions:

• Hypersensitivity: Known hypersensitivity to hCG, any component of the formulation, or related gonadotropin products

• Pregnancy: hCG is contraindicated during established pregnancy (Pregnancy Category X for weight loss indication; Category C for approved fertility indications)

• Hormone-dependent malignancies: Active or suspected hormone-dependent tumors including breast cancer, ovarian cancer, uterine cancer, prostate cancer, or other sex hormone-dependent neoplasms

• Uncontrolled thyroid disease: Untreated or inadequately controlled thyroid dysfunction (hypothyroidism or hyperthyroidism)

• Uncontrolled adrenal dysfunction: Active adrenal insufficiency or uncontrolled adrenal disorders

• Pituitary tumors: Presence of pituitary tumor or other intracranial lesions

• Abnormal uterine bleeding of undetermined origin: Unexplained vaginal bleeding requiring diagnostic evaluation

• Ovarian cysts or enlargement: Pre-existing ovarian cysts or ovarian enlargement not due to polycystic ovary syndrome

• Primary ovarian failure: Documented primary ovarian insufficiency or premature ovarian failure

• Primary testicular failure: Primary testicular failure in males (will not respond to hCG stimulation)

• Precocious puberty: Children with precocious puberty should not receive hCG

Warnings and Serious Adverse Effects

Ovarian Hyperstimulation Syndrome (OHSS)

OHSS represents the most serious complication of hCG use in fertility treatments, occurring in 1-3% of stimulated cycles with moderate-to-severe presentations. This potentially life-threatening condition results from excessive ovarian response to gonadotropin stimulation, characterized by massive ovarian enlargement, increased vascular permeability, third-space fluid accumulation, and hemoconcentration. Symptoms typically develop 3-10 days post-hCG administration and include severe abdominal pain and distension, nausea, vomiting, diarrhea, rapid weight gain (>2-3 pounds/day), decreased urine output, and dyspnea. Severe OHSS can progress to complications including pleural effusions, ascites, pericardial effusion, acute respiratory distress syndrome, thromboembolic events (stroke, pulmonary embolism, deep vein thrombosis), ovarian torsion, renal failure, and rarely death.

Risk factors for OHSS include: young age (<35 years), low body weight, PCOS, high antral follicle count (>24), rapid estradiol rise, peak estradiol >3,000-4,000 pg/mL, >20 follicles ≥11mm, retrieval of >15-20 oocytes, pregnancy occurrence (endogenous hCG exacerbates syndrome), and prior OHSS history. Prevention strategies include cycle cancellation when risk factors present, coasting (withholding gonadotropins while monitoring), dual-trigger protocols with reduced hCG doses, GnRH agonist trigger in antagonist protocols, elective embryo cryopreservation with delayed transfer, and prophylactic cabergoline or albumin administration. Patients should be counseled on OHSS symptoms and instructed to seek immediate medical attention if severe symptoms develop.

Thromboembolic Events

HCG administration in the context of controlled ovarian stimulation increases thromboembolic risk through multiple mechanisms including estrogen-induced hypercoagulability, hemoconcentration from OHSS, and vascular endothelial changes. Reported thromboembolic events include deep vein thrombosis, pulmonary embolism, arterial thrombosis, stroke, and myocardial infarction, with incidence rates of 0.1-0.3% in ART cycles. Risk is substantially elevated in patients who develop OHSS, with rates approaching 1-2% in severe cases. Additional risk factors include thrombophilia (Factor V Leiden, prothrombin mutation, antiphospholipid antibodies), obesity, advanced maternal age, immobilization, and personal or family history of thromboembolism. High-risk patients may benefit from thromboprophylaxis with low-molecular-weight heparin during and after stimulation cycles.

Multiple Gestation

HCG use in ovulation induction significantly increases multiple pregnancy risk, with twin rates of 15-30% and higher-order multiple rates of 3-5% depending on the number of mature follicles at trigger. Multiple gestations carry substantially increased maternal risks (preeclampsia, gestational diabetes, cesarean delivery, postpartum hemorrhage) and fetal/neonatal risks (preterm birth, low birth weight, twin-to-twin transfusion syndrome, cerebral palsy, neonatal death). Careful ultrasound monitoring with cycle cancellation when excessive follicular development occurs (typically >4-5 mature follicles in non-IVF cycles) is essential for risk mitigation.

Ectopic Pregnancy

Patients conceiving after hCG-triggered cycles face increased ectopic pregnancy risk (2-5% in ART cycles vs. 1-2% in general population), particularly those with tubal factor infertility, prior ectopic pregnancy, or pelvic inflammatory disease history. Early pregnancy monitoring with serial beta-hCG measurements and transvaginal ultrasound is recommended to ensure intrauterine pregnancy location.

Ovarian Torsion

Enlarged ovaries following gonadotropin stimulation and hCG administration are susceptible to torsion, presenting with acute severe unilateral pelvic pain, nausea, vomiting, and adnexal tenderness. This surgical emergency requires prompt diagnosis via Doppler ultrasound and urgent laparoscopic intervention to preserve ovarian function. Incidence ranges from 0.1-0.2% of stimulated cycles, with higher rates in OHSS cases.

Common Adverse Effects

Injection site reactions (10-30%): Pain, erythema, swelling, bruising at injection site; typically mild and self-limited

Headache (10-20%): Usually mild-to-moderate intensity; may be related to hormonal changes

Fatigue and irritability (5-15%): Related to hormonal fluctuations and treatment stress

Abdominal bloating and discomfort (15-25%): Mild ovarian enlargement and fluid retention; distinguish from OHSS

Breast tenderness (5-10%): Due to elevated estrogen and progesterone levels

Nausea (5-10%): Usually mild; severe nausea may indicate OHSS

Mood changes (5-10%): Emotional lability, anxiety, depression related to hormonal effects and treatment stress

Acne and skin changes (3-5%): Particularly in males receiving hCG for hypogonadism

Gynecomastia (5-10% in males): Breast enlargement in males due to aromatization of testosterone to estradiol

Fluid retention and edema (5-10%): Mild peripheral edema; severe cases suggest OHSS

Special Population Warnings

Pregnancy and Lactation

HCG is classified as Pregnancy Category X when used for weight loss (contraindicated) and Category C for approved fertility indications. The medication should not be administered during established pregnancy except in specific early pregnancy support protocols under specialist supervision. While hCG is a natural pregnancy hormone, exogenous administration during pregnancy has not been adequately studied for safety. Small amounts of hCG may be excreted in breast milk, though effects on nursing infants are unknown; use caution if administering to lactating women.

Pediatric Patients

In pediatric populations, hCG is approved only for prepubertal cryptorchidism treatment. Precocious puberty represents an absolute contraindication. When used for cryptorchidism, monitor for signs of precocious sexual development, aggressive behavior, or premature epiphyseal closure. Long-term safety data in adolescents receiving hCG for hypogonadotropic hypogonadism induction are limited to specialized protocols; treatment should occur only under pediatric endocrinology supervision with careful monitoring of growth, bone age, and pubertal development.

Cardiovascular Disease

Patients with pre-existing cardiovascular disease, hypertension, or cardiac risk factors require careful evaluation before hCG administration due to fluid retention risks and potential for exacerbating heart failure or hypertension. The medication should be used with caution in patients with renal disease, migraine, epilepsy, or asthma, as fluid retention may worsen these conditions.

Monitoring Requirements

Pre-treatment evaluation:

• Comprehensive fertility assessment including hormone levels (FSH, LH, estradiol, AMH, testosterone in males)

• Transvaginal ultrasound to assess ovarian morphology and exclude cysts

• Pregnancy test to exclude existing pregnancy

• Thyroid function tests (TSH, free T4)

• Prolactin level if indicated

• Screening for contraindications and risk factors

During treatment:

• Serial transvaginal ultrasound monitoring of follicular development

• Serum estradiol levels (every 2-3 days during stimulation)

• Assessment for OHSS symptoms at each visit

• Post-trigger monitoring for OHSS development (days 3-10)

Post-treatment:

• Pregnancy testing 12-14 days post-embryo transfer or insemination

• Early pregnancy ultrasound to confirm intrauterine location and viability

• Continued OHSS surveillance through first trimester if pregnant

• In males: testosterone monitoring, semen analysis, testicular examination

Drug Abuse and Dependence

HCG has been misused in athletic doping to stimulate endogenous testosterone production and mask anabolic steroid use. It is prohibited by the World Anti-Doping Agency and most sports organizations. HCG has also been fraudulently marketed for weight loss in combination with very low-calorie diets, a use that is not FDA-approved and for which there is no credible scientific evidence of efficacy. Such use is contraindicated and potentially dangerous.

Pharmacokinetics

Human Chorionic Gonadotropin exhibits distinct pharmacokinetic properties that influence its clinical application and dosing strategies. Following subcutaneous or intramuscular administration, hCG demonstrates relatively slow absorption with peak serum concentrations typically achieved within 12-24 hours post-injection. The bioavailability of subcutaneous hCG administration ranges from 40-70%, which is lower than intramuscular injection but provides more consistent absorption kinetics and improved patient tolerability. The volume of distribution is relatively limited, approximating extracellular fluid volume, as the large molecular weight (approximately 36.7 kDa) and hydrophilic nature of the glycoprotein restrict tissue penetration.

The elimination half-life of hCG varies depending on the route of administration and formulation, typically ranging from 24-36 hours for intramuscular injection and slightly shorter (20-30 hours) for subcutaneous administration. This prolonged half-life compared to endogenous LH (approximately 20 minutes) results from extensive glycosylation, particularly the presence of four N-linked glycosylation sites on the beta subunit and one on the alpha subunit. These carbohydrate moieties protect the molecule from rapid proteolytic degradation and reduce renal clearance. Metabolism occurs primarily through receptor-mediated endocytosis in target tissues (ovaries, testes) and hepatic degradation, with renal excretion representing the major elimination pathway. Approximately 10-20% of administered hCG is excreted unchanged in urine, which forms the basis for urinary hCG detection in pregnancy testing and doping control.

Pharmacodynamics

The pharmacodynamic effects of hCG are mediated through sustained activation of the LH/CG receptor, producing dose-dependent and time-dependent responses in target tissues. In ovarian tissue, a single dose of 5,000-10,000 IU hCG triggers a cascade of events mimicking the endogenous LH surge: resumption of meiosis in oocytes arrested at prophase I, cumulus expansion through hyaluronic acid synthesis and matrix remodeling, activation of proteolytic enzymes (plasminogen activator, collagenase) that weaken the follicular wall, and prostaglandin synthesis that facilitates follicular rupture. Ovulation typically occurs 36-42 hours post-hCG administration, allowing precise timing of intercourse, insemination, or oocyte retrieval procedures.

Following ovulation, hCG supports corpus luteum formation and function, stimulating progesterone production essential for endometrial transformation and early pregnancy support. Peak progesterone levels are achieved 5-9 days post-hCG administration, with sustained elevation for 10-14 days in the absence of pregnancy or continued hCG supplementation. In males, hCG administration produces dose-dependent increases in serum testosterone, with levels typically rising within 2-4 hours and peaking at 48-72 hours post-injection. Doses of 1,500-3,000 IU administered 2-3 times weekly maintain testosterone levels within the physiological range in hypogonadotropic hypogonadal men. Chronic hCG stimulation also promotes testicular growth, with increases in testicular volume of 30-50% observed after 3-6 months of therapy in hypogonadal males.

Drug Interactions and Special Considerations

Pharmacologically, hCG exhibits minimal direct drug-drug interactions due to its peptide nature and receptor-specific mechanism of action. However, important clinical interactions exist with medications affecting gonadal function or hormone metabolism. Concurrent use of gonadotropin-releasing hormone (GnRH) agonists or antagonists can modulate hCG effectiveness, with GnRH antagonists commonly used in ART protocols to prevent premature LH surges before scheduled hCG administration. The combination of hCG with other gonadotropins (FSH, LH, hMG) is standard practice in controlled ovarian stimulation, with synergistic effects on follicular development and oocyte maturation.

Glucocorticoids and other immunosuppressive agents may theoretically alter hCG receptor expression or signaling, though clinical significance remains unclear. Thyroid hormones can influence gonadotropin receptor sensitivity, and thyroid dysfunction should be corrected before initiating fertility treatments involving hCG. Importantly, hCG does not undergo hepatic cytochrome P450 metabolism, eliminating concerns about interactions with CYP enzyme inhibitors or inducers. Renal impairment may prolong hCG half-life and increase exposure, though dose adjustments are rarely necessary in clinical practice. The immunogenic potential of hCG, particularly with repeated administrations, can lead to antibody formation in rare cases, potentially reducing therapeutic efficacy and necessitating alternative treatment strategies.